327 related articles for article (PubMed ID: 23354868)
1. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.
Vincent M; Bessard A; Cochonneau D; Teppaz G; Solé V; Maillasson M; Birklé S; Garrigue-Antar L; Quéméner A; Jacques Y
Int J Cancer; 2013 Aug; 133(3):757-65. PubMed ID: 23354868
[TBL] [Abstract][Full Text] [Related]
2. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
[TBL] [Abstract][Full Text] [Related]
3. Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.
Vincent M; Teppaz G; Lajoie L; Solé V; Bessard A; Maillasson M; Loisel S; Béchard D; Clémenceau B; Thibault G; Garrigue-Antar L; Jacques Y; Quéméner A
MAbs; 2014; 6(4):1026-37. PubMed ID: 25072059
[TBL] [Abstract][Full Text] [Related]
4. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
6. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer.
Bessard A; Solé V; Bouchaud G; Quéméner A; Jacques Y
Mol Cancer Ther; 2009 Sep; 8(9):2736-45. PubMed ID: 19723883
[TBL] [Abstract][Full Text] [Related]
7. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
[TBL] [Abstract][Full Text] [Related]
8. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
[TBL] [Abstract][Full Text] [Related]
9. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.
Cheung NK; Canete A; Cheung IY; Ye JN; Liu C
Int J Cancer; 1993 May; 54(3):499-505. PubMed ID: 8509225
[TBL] [Abstract][Full Text] [Related]
10. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
[TBL] [Abstract][Full Text] [Related]
11. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.
Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA
Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646
[TBL] [Abstract][Full Text] [Related]
12. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
[TBL] [Abstract][Full Text] [Related]
13. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery.
Kowalczyk A; Wierzbicki A; Gil M; Bambach B; Kaneko Y; Rokita H; Repasky E; Fenstermaker R; Brecher M; Ciesielski M; Kozbor D
Cancer Immunol Immunother; 2007 Sep; 56(9):1443-58. PubMed ID: 17597331
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
[TBL] [Abstract][Full Text] [Related]
15. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
Neal ZC; Yang JC; Rakhmilevich AL; Buhtoiarov IN; Lum HE; Imboden M; Hank JA; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
Clin Cancer Res; 2004 Jul; 10(14):4839-47. PubMed ID: 15269160
[TBL] [Abstract][Full Text] [Related]
16. IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment.
Desbois M; Béal C; Charrier M; Besse B; Meurice G; Cagnard N; Jacques Y; Béchard D; Cassard L; Chaput N
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32532840
[TBL] [Abstract][Full Text] [Related]
17. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
Lode HN; Xiang R; Varki NM; Dolman CS; Gillies SD; Reisfeld RA
J Natl Cancer Inst; 1997 Nov; 89(21):1586-94. PubMed ID: 9362156
[TBL] [Abstract][Full Text] [Related]
18. An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site.
Kermer V; Baum V; Hornig N; Kontermann RE; Müller D
Mol Cancer Ther; 2012 Jun; 11(6):1279-88. PubMed ID: 22491823
[TBL] [Abstract][Full Text] [Related]
19. Human monoclonal antibody to tumor-associated ganglioside GD2.
Katano M; Saxton RE; Irie RF
J Clin Lab Immunol; 1984 Nov; 15(3):119-26. PubMed ID: 6099419
[TBL] [Abstract][Full Text] [Related]
20. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]